ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Ear, nose and throat · Int Forum Allergy Rhinol · 2026-07-29

Prespecified secondary analysis of a phase 3 trial in 63 Chinese adults with severe chronic rhinosinusitis with nasal polyps: tezepelumab vs placebo gave numerically greater 52-week falls in nasal-polyp score (LS mean difference -2.03) and nasal congestion score.

Secondary analysisn = 63
Hu et al. Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial
Allergy and immunology · J Allergy Clin Immunol · 2026-07-03

Network meta-analysis of 15 RCTs (3,642 patients) with severe chronic rhinosinusitis with nasal polyps: dupilumab and stapokibart (20–24 weeks) and dupilumab and tezepelumab (48–56 weeks) reduced polyp and congestion scores more than other biologics; safety was comparable.

Meta-analysisn = 3,642
Ouranos et al. Comparative efficacy of biologic agents for severe chronic rhinosinusitis with nasal polyps: Systematic review and network meta-analysis
Respiratory · Lancet Respir Med · 2026-05-18

In 122 adults with severe oral corticosteroid-dependent asthma, tezepelumab gave greater oral corticosteroid dose reduction at week 28 than placebo while maintaining control (OR 2·93; p=0·0034). Trial stopped early (122 of 207 planned); exacerbations 30% vs 59%.

RCTn = 122
Wechsler et al. Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial
Allergy and immunology · Ann Allergy Asthma Immunol · 2026-02-13

Secondary analysis of the NAVIGATOR trial (1,059 patients with severe uncontrolled asthma; 165 with nasal polyps): more tezepelumab than placebo recipients reported better sleep, activity and exertion tolerance at week 52, more so with nasal polyps.

Secondary analysisn = 1,059
Lugogo et al. Tezepelumab's effects on patient-reported symptoms in severe asthma, overall and with history of comorbid chronic rhinosinusitis with nasal polyps (CRSwNP)

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.